SOLVE-RD program will sequence more than 500 human genomes with SMRT Sequencing MENLO PARK, Calif. , Sept. 05, 2019 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (Nasdaq:PACB), a leading provider of high-quality sequencing of genomes, transcriptomes and epigenomes, today announced

MENLO PARK, Calif. , Aug. 06, 2019 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its second quarter ended June 30, 2019 . On April 24, 2019 , the Company announced the commercial launch of the Sequel II System and the Single

Identification of pathogenic structural variants with SMRT Sequencing improves solve rate for rare and Mendelian diseases MENLO PARK, Calif. , June 13, 2019 (GLOBE NEWSWIRE) -- While DNA sequencing tools have been useful for determining the genetic cause of many diseases, there remain a large

MENLO PARK, Calif. , May 03, 2019 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its first quarter ended March 31, 2019 , as attached. During the first quarter of 2019, the Company announced that it commenced its Early Access Program

New system is ideally suited for comprehensive variant detection, large genome de novo assembly, human structural variant characterization, whole transcriptome analysis, and more MENLO PARK, Calif. , April 24, 2019 (GLOBE NEWSWIRE) -- Pacific Biosciences of California Inc.

In a retrospective study, Anthony Nolan Research Institute found SMRT ® Sequencing identified superior HLA matches, which are critical in determining successful transplant outcomes MENLO PARK, Calif. , April 02, 2019 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc.

Customers to Present Results from a Range of Market Areas Including Human Biomedical, Evolutionary Biology, and AgBio; Company to Present New Methods for Single-Cell Isoform Sequencing and Low-Input DNA Protocol MENLO PARK, Calif. , Feb. 26, 2019 (GLOBE NEWSWIRE) -- Pacific Biosciences of

MENLO PARK, Calif. , Feb. 11, 2019 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its fourth quarter and year ended December 31, 2018 , as attached. During the fourth quarter of 2018, the Company stated that it was targeting early

Improved Reference Genome for Aedes aegypti, Carrier of Zika Virus and Other Public Health Threats, Published in Nature MENLO PARK, Calif. , Nov. 14, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California Inc. , (Nasdaq:PACB), the leading provider of high-quality sequencing of genomes,

MENLO PARK, Calif. , Nov. 01, 2018 (GLOBE NEWSWIRE) -- Pacific Biosciences of California, Inc. (NASDAQ: PACB) today announced financial results for its third quarter ended September 30, 2018 . Total revenue for the third quarter of 2018 was $18.2 million , compared to $23.5 million for the third